+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

World Organ Transplant Immunosuppressant Drugs Market - Opportunities and Forecasts, 2017 - 2023

  • PDF Icon

    Report

  • September 2019
  • Region: Global
  • Allied Market Research
  • ID: 3773039
Organ transplant immunosuppressant drugs are the category of drugs which are administered to minimize the chances of organ rejection after transplantation. When a person undergoes any transplantation, the body recognizes the transplant as a foreign tissue and attacks it, resulting in rejection. These drugs dilute the immune system, hence reducing the reaction towards the transplant. The factors driving this market include the advancements made in tissue engineering and organ transplantations. These transplantations help in survival of many patients as well as enhance the quality of life. The lack of availability of organs and high cost of transplantation are the limitations for the growth of this market. The increase in use of tissue engineering for generation of implants provides growth opportunity to this market.

GLOBAL ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS THERAPEUTICS MARKET ANALYSIS

On the basis of therapeutics, this market is classified into heart transplant, lung transplant, kidney transplant and liver transplant. Kidney transplant has a well established market although heart transplant is expected to have potential growth.

ORGAN TRANSPLANT IMMUNOSUPPRESSANT DRUGS GEOGRAPHY MARKET ANALYSIS

On the basis of geography, this market is classified into North America, Europe, Asia-Pacific and rest of the world (RoW). Asia-Pacific region is expected to have greater share in this market in the coming years. This growth would be due to promotion of medical tourism in these countries.

COMPETITIVE LANDSCAPE

The major companies included in the report are AstellasPharma, Genzyme Corporation, Accord Healthcare Ltd., Watson Pharmaceuticals, Inc., Novartis AG, Mylan Laboratories, Inc., GlaxoSmithKline plc, and Hoffman La Roche. Key companies in the report are seeking for approval strategy for the commercialization of their pipeline drugs. Therefore, the companies are adopting approval and clearance as key developmental strategies.

HIGH LEVEL ANALYSIS

Organ transplant immunosuppressant drugs market has accelerated the growth of rapid organ transplant by reducing the harmful side effects such as autoimmune diseases. These novel drug therapies are strategically analyzed in the report in order to provide comparative benefits. The report is also focusing on the regulatory issues and commercial mandate that are hindering the growth. Porter’s five forces model is strategically analyzed in the report to project current and future market scenarios. The value chain analysis of the organ transplant immunosuppressant drugs market is dealt strategically. Top wining strategies adopted by the key players competing in this market are critically analyzed through primaries.

KEY BENEFITS

Intelligence from key market segments through top investment pockets would help in providing strategic assistance to decision markers.
Analysis of key market players and strategies adopted by them are dealt to give an insight on top contenders in the market
This report gives a detailed analysis of drivers and factors limiting market expansion of organ transplant immunosuppressant drugs
Projections are made for the period of 2014-2020 by considering current market scenario and future potential
Porter’s five forces and SWOT analysis discussed would help in making strategic decisions

KEY MARKET SEGMENTS

The global Organ transplant immunosuppressant drugs market is segmented into therapeutics, commercialized products and geography.

MARKET BY THERAPEUTICS

Heart Transplant
Lung Transplant
Kidney Transplant
Liver Transplant

MARKET BY COMMERCIALIZED PRODUCTS

Zenapax
Prograf
Cellcept
Myfortic
Neoral

MARKET BY GEOGRAPHY

North America
Europe
Asia-Pacific
RoW

Methodology

The analyst offers exhaustive research and analysis based on a wide variety of factual inputs, which largely include interviews with industry participants, reliable statistics, and regional intelligence. The in-house industry experts play an instrumental role in designing analytic tools and models, tailored to the requirements of a particular industry segment. The primary research efforts include reaching out participants through mail, tele-conversations, referrals, professional networks, and face-to-face interactions.

They are also in professional corporate relations with various companies that allow them greater flexibility for reaching out to industry participants and commentators for interviews and discussions.

They also refer to a broad array of industry sources for their secondary research, which typically include; however, not limited to:

  • Company SEC filings, annual reports, company websites, broker & financial reports, and investor presentations for competitive scenario and shape of the industry
  • Scientific and technical writings for product information and related preemptions
  • Regional government and statistical databases for macro analysis
  • Authentic news articles and other related releases for market evaluation
  • Internal and external proprietary databases, key market indicators, and relevant press releases for market estimates and forecast

Furthermore, the accuracy of the data will be analyzed and validated by conducting additional primaries with various industry experts and KOLs. They also provide robust post-sales support to clients.

Loading
LOADING...